Journal Reviews

Orbit journal cover

Therapeutic options for advanced cutaneous basal (BCC) and squamous cell carcinomas (SCC)

9 August 2023 | | Oculoplastics, Orbit | Basal cell carcinoma, hedgehog inhibitors, imiquimod, immunotherapy, squamous cell carcinoma

This article discusses the use of topical and systemic therapy in the management of advanced periocular tumours. It focuses on those that have gained United States Food and Drug Administration approval; namely imiquimod, vismodegib, sonidegib, pembrolizumab and cemiplimab. Imiquimod is...

Systemic rituximab immunotherapy in the management of primary ocular adnexal lymphoma single institutional experience

1 October 2015 | | Oculoplastics, Orbit | Extranodal marginal zone lymphoma, Rituximab, immunotherapy, lymphoma, ocular adnexa

Ocular adnexal lymphomas constitute 2% of all non-Hodgkin’s disease and 5-15% of all extranodal lymphomas and are usually localised, low-grade and of B-cell origin. This opens them up to potential treatment with a systemic monoclonal antibody-based drug (rituximab) directed at...